Health & Care Cluster

of Large Scale Pilots



RADICAL HEALTH FESTIVAL Helsinki 12 June 2023 Al in hospitals: are we ready for it?"
Challenges and opportunities of Al deployment in hospitals



Will Al deeply change the way we deal with patients affected by Parkinson disease?

Laura Mäkitie, Neurologist at Helsinki University Hospital (HUS)



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement n.10101016902. This documet reflects the autor's view and the Commission is not responsable for any use that may be made of the information it contains.

Parkinson's disease is chronic, progressive disease without cure

Current follow-up: Visits every 6-12 months

Visit to the neurologist or GP

Well-being of the patient and accuracy of the treatment plan is evaluated based on physical examination and history told by the patient

Fluctuations and progression

Symptoms may fluctuate hourly or daily. Disease is proressing slowly.

The number of patients is increasing globally

Complexity of the disease demands high specialization of health care











Symptoms

New motor, non-motor and cognitive symptoms appear as the disease progresses

Adjustment of treatment


Detailed knowledge of patient symptoms is needed for timely and accurate adjustment of medication and implementation on device aided treatments











What if we could do the monitoring of the patients between the visits?

And Al would help analyzing the data?









Facts about AICCELERATE Parkinson-Pilot

AIM

To provide a decission support tool for a doctor to

- Anticipate the progression of the disease with prediction algorithms
- Monitor the symptoms between the visits

DATA SETS

For development

- Medical registry data for the development of prediction algorithms
 - 5100 patients in HUS
 - 1000 patients in UNIPD
- Prospective remote monitoring data for symptom follow-up
- Cohort of 200 patients from HUS and UNIPD

DEVICES & APPS

For remote monitoring

- Al-enhanced motion capture and symptom diary (NeuroPath)
- Ignite2 wearable (Polar): mobility, sleep, heart rate
- Cognitive assessment app (UNIPD)
- Medicine dispenser robot (Evondos)
- MyPath digital service for patients (HUS)











Smart Hospital Care Pathway Engine 4. User interfaces Technical components 3. Al models **USER ACCESS** SHCP ENGINE AI/ML MODULE Graph Al optimisation/ clinical frontend 1. EHRs model selection ML Algorithms **GRPC** Data Data ingestion extraction TRAIN HL7 FHIR suite suite MODEL social robot SERVE •••• = 0 Structured Data 面面 Warehouse Hospital Apply AI/ML (REST DataBase digital twin monitoring Al Data Enrichment Suite Custom Data **APIs** Collection APIs WEATHER CALENDAR **S**FIWARE **SCORPIOBROKER** OTHER DATA SOURCES AUTHENTICATION **STATISTICS** 2. Remote APPS LAYER **WEARABLES** monitoring data APIS LAYER BLE, REST, MOTT ROBOTICS APPLICATION LAYER IoT



Deployment enhancing elements in AICCELERATE



Modular structure of the Smart Hospital Care Pathway Engine allows local deployment with existing platforms and data processing solutions



Medical device regulation and CE-marking demands integrated to development plan from the beginning



development team
(Al-experts, data
analyst, ITarchitects, clinicians,
patients, lawyers,
economists)

Multidisciplinary









Doctors are interested in change, if technical tools are integrated to existing platforms and evidence-based. Patients are ready to try Al and remotemonitoring, if they or their doctors benefit for it.



C Godoy Junior, F Miele, L Mäkitie, LJ Bakker, E Fiorenzato, C Uyl-De Groot, K Redekop, W van Deen, Patients and Neurologists' Preferences for Remote Patient Monitoring and Artificial Intelligence to Improve Parkinson's Disease Management, Value in Health, Volume 25, Issue 12, Supplement, 2022, Page S410, ISSN 1098-3015, https://doi.org/10.1016/j.jval.2022.09.2038.



Al offers important new opportunities to improve care processes, quality of daily life and autonomy of Parkinson's Disease patients















This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement n.10 10 16902. This documet reflects the autor's view and the Commision is not responsable for any use that may be made of the information it contains.